Seeking Alpha

Vanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major...

Vanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major depressive disorder). VNDA says it will continue to pursue tasimelteon as a treatment for blind people with Non-24-Hour Disorder. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)